bullish
Terumo: Not Just an Opportune COVID Play but a Business with Solid Long-Term Prospects
271 Views20 Apr 2020 13:53
Terumo Corp (4543 JP) provides innovative medical solutions through its extensive business portfolio which ranges from vascular intervention and...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 11-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Gilead: Will Immunomedics Be Gilead’s Next Pharmasset?30 Sep 2020
- Terumo: Pandemic Impacts Q1 but Recovery Is Expected in the 2nd Half10 Aug 2020
- Gilead to Acquire a Stake in Arcus Biosciences; Offer May Come at a Large Premium21 Apr 2020
- Terumo: Not Just an Opportune COVID Play but a Business with Solid Long-Term Prospects20 Apr 2020
- M3 Inc: M&A Deals to Support Global Expansion While Medical Platform Offers Solid LT Growth27 Mar 2020
- Fujifilm’s Shares Hit Daily Upper Limit on COVID Trial Drug Boost18 Mar 2020
x